In this regard, we conducted this systematic review and meta-analysis of randomized controlled trials (RCTs) to investigate the effects of SGLT2 inhibitors on individual renal outcomes compared with placebo or other antidiabetic drugs in patients with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.